Patent intelligence · US
US 9844530
Ophthalmic solutions for glaucoma and conjunctivitis treatment
Ophthalmic solutions for glaucoma and conjunctivitis treatment
Patent details — US 9844530
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 19, 2017
- Expiration
- Dec 14, 2037
- Applicant
- AXIM BIOTECHNOLOGIES. INC.
- Claims
- 18
- CPC classes
- A61K, A61K31/05, A61K31/352, A61K31/658
Quick answer
US 9844530 (Ophthalmic solutions for glaucoma and conjunctivitis treatment) is held by AXIM BIOTECHNOLOGIES. INC.. Status: granted. Granted Dec 19, 2017. Expires Dec 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXIM BIOTECHNOLOGIES. INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/05, A61K31/352, A61K31/658, A61K9/0048, A61K9/08
More from AXIM BIOTECHNOLOGIES. INC.
Related pharmaceutical patents in our USPTO index.
-
US 12391732
Articles comprising a silk polypeptide for antigen delivery
granted -
US 12379385
Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
granted -
US 12318397
Methods and compositions for testosterone production
granted -
US 12290524
Methods and compositions for testosterone production
granted -
US 12171837
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
granted -
US 12168718
Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel
granted -
US 12144876
Security mechanisms for radiopharmaceutical elution system and elution process
granted -
US 12133890
Antigen-binding polypeptide targeting B7H3 and application thereof
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 9844530?
US 9844530 (Ophthalmic solutions for glaucoma and conjunctivitis treatment) is held by AXIM BIOTECHNOLOGIES. INC.. Status: granted. Granted Dec 19, 2017. Expires Dec 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9844530?
AXIM BIOTECHNOLOGIES. INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.
When does US 9844530 expire?
Our index shows an expiration date of Dec 14, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.